Argitalpenak (28) LEYRE SERRANO FERNÁNDEZ argitalpenak

2024

  1. Basic host response parameters to classify mortality risk in COVID-19 and community-acquired pneumonia

    Scientific reports, Vol. 14, Núm. 1, pp. 12726

2023

  1. High-flow nasal cannula oxygen therapy for the treatment of acute respiratory failure secondary to SARS-CoV-2 pneumonia out of ICU

    Clinical Respiratory Journal, Vol. 17, Núm. 9, pp. 905-914

  2. Impact of outdoor air pollution on severity and mortality in COVID-19 pneumonia

    Science of the Total Environment, Vol. 894

  3. Impact of severe lymphopenia on the early prediction of clinical outcome in hospitalized patients with pneumococcal community-acquired pneumonia

    Infection, Vol. 51, Núm. 5, pp. 1319-1327

  4. Is the long-term mortality similar in COVID-19 and community-acquired pneumonia?

    Frontiers in Medicine, Vol. 10

  5. Short- and long-term prognosis of patients with community-acquired Legionella or pneumococcal pneumonia diagnosed by urinary antigen testing

    International Journal of Infectious Diseases, Vol. 134, pp. 106-113

  6. Ten Issues for Updating in Community-Acquired Pneumonia: An Expert Review

    Journal of Clinical Medicine, Vol. 12, Núm. 21

  7. Validation of IDSA/ATS Guidelines for ICU Admission in Adults Over 80 Years Old With Community-Acquired Pneumonia

    Archivos de Bronconeumologia, Vol. 59, Núm. 1, pp. 19-26

2022

  1. Author Correction: Machine learning-based model for prediction of clinical deterioration in hospitalized patients by COVID 19 (Scientific Reports, (2022), 12, 1, (7097), 10.1038/s41598-022-09771-z)

    Scientific Reports

  2. Bacteraemic pneumococcal pneumonia and SARS-CoV-2 pneumonia: differences and similarities

    International Journal of Infectious Diseases, Vol. 115, pp. 39-47

  3. Bacteremic pneumococcal pneumonia: arrhythmogenic disease

    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia

  4. COVID-19 in young and middle-aged adults: predictors of poor outcome and clinical differences

    Infection, Vol. 50, Núm. 1, pp. 179-189

  5. Early Recognition of Low-Risk SARS-CoV-2 Pneumonia: A Model Validated With Initial Data and Infectious Diseases Society of America/American Thoracic Society Minor Criteria

    Chest, Vol. 162, Núm. 4, pp. 768-781

  6. Estimating the risk of bacteraemia in hospitalised patients with pneumococcal pneumonia

    Journal of Infection, Vol. 85, Núm. 6, pp. 644-651

2021

  1. Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial)

    PharmacoEconomics, Vol. 39, Núm. 3, pp. 331-343

  2. New-onset atrial fibrillation in patients with pneumococcal pneumonia. Impact of timing and duration on short- and medium-term mortality

    Journal of Infection, Vol. 82, Núm. 1, pp. 67-75

  3. Predictors of mortality of COVID-19 in the general population and nursing homes

    Internal and Emergency Medicine, Vol. 16, Núm. 6, pp. 1487-1496

  4. Pulmonary Function in Early Follow-up of patients with COVID-19 Pneumonia

    Archivos de Bronconeumologia, Vol. 57, pp. 75-76

  5. RDW-based clinical score to predict long-term survival in community-acquired pneumonia: a European derivation and validation study

    Internal and Emergency Medicine, Vol. 16, Núm. 6, pp. 1547-1557

2020

  1. Cost-Effectiveness of Three Alternative Boosted Protease Inhibitor-Based Second-Line Regimens in HIV-Infected Patients in West and Central Africa

    PharmacoEconomics - Open, Vol. 4, Núm. 1, pp. 45-60